Drug Profile
Research programme: antibody therapeutics - Northern Biologics
Alternative Names: NB 0893; NB 6253; NB 6377Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator University Health Network; University of Toronto
- Developer Northern Biologics
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunologic receptor modulators; Immunomodulators; Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Fibrosis
Most Recent Events
- 14 May 2020 Northern Biologics has been acquired by Boehringer Ingelheim
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)